Page 64 - OR-1-1

doi: 10.1016/j.cell.2020.11.017 pathological features of human brain organoids. Nat
Commun. 2021;12:280.
101. Pașca SP, Arlotta P, Bateup HS, et al. A framework for neural
organoids, assembloids and transplantation studies. Nature. doi: 10.1038/s41467-020-20440-5
2024;639:315-320.
113. Jin Y, Li F, Li Z, et al. Modeling Lewy body disease with SNCA
doi: 10.1038/s41586-024-08487-6 triplication iPSC-derived cortical organoids and identifying
therapeutic drugs. Sci Adv. 2024;10:eadk3700.
102. Xu X, Gao Y, Dai J, et al. Gastric cancer assembloids derived
from patient‐derived xenografts: A preclinical model for doi: 10.1126/sciadv.adk3700
therapeutic drug screening. Small Methods. 2024;8:2400204. 114. Hu W, Lazar MA. Modelling metabolic diseases and drug
doi: 10.1002/smtd.202400204 response using stem cells and organoids. Nat Rev Endocrinol.
2022;18:744-759.
103. Zhang Y, Hu Q, Pei Y, et al. A patient-specific lung
cancer assembloid model with heterogeneous tumor doi: 10.1038/s41574-022-00733-z
microenvironments. Nat Commun. 2024;15:3382. 115. Jin Y, Kim J, Lee JS, et al. Vascularized liver organoids
doi: 10.1038/s41467-024-47737-z generated using induced hepatic tissue and dynamic liver‐
specific microenvironment as a drug testing platform. Adv
104. Wu S, Hong Y, Chu C, et al. Construction of human 3D Funct Mater. 2018;28:1801954.
striato-nigral assembloids to recapitulate medium spiny
neuronal projection defects in Huntington’s disease. Proc doi: 10.1002/adfm.201801954
Natl Acad Sci. 2024;121:e2316176121. 116. Xu H, Jiao Y, Qin S, Zhao W, Chu Q, Wu K. Organoid
doi: 10.1073/pnas.2316176121 technology in disease modelling, drug development,
personalized treatment and regeneration medicine. Exp
105. Bai L, Zhou D, Li G, Liu J, Chen X, Jiacan S. Engineering Hematol Oncol. 2018;7:30.
bone/cartilage organoids: Strategy, progress, and application.
Bone Res. 2024;12:66. doi: 10.1186/s40164-018-0122-9
doi: 10.1038/s41413-024-00376-y 117. Artegiani B, Van Voorthuijsen L, Lindeboom RGH,
et al. Probing the tumor suppressor function of BAP1 in
106. Nero C, Vizzielli G, Lorusso D, et al. Patient-derived CRISPR-engineered human liver organoids. Cell Stem Cell.
organoids and high grade serous ovarian cancer: From 2019;24:927-943.e926.
disease modeling to personalized medicine. J Exp Clin
Cancer Res. 2021;40:1-14. doi: 10.1016/j.stem.2019.04.017
doi: 10.1186/s13046-021-01917-7 118. Nakamura T, Sato T. Advancing intestinal organoid
technology toward regenerative medicine. Cell Mol
107. Grenier K, Kao J, Diamandis P. Three-dimensional modeling Gastroenterol Hepatol. 2018;5:51-60.
of human neurodegeneration: Brain organoids coming of
age. Mol Psychiatry. 2020;25:254-274. doi: 10.1016/j.jcmgh.2017.10.006
doi: 10.1038/s41380-019-0500-7 119. Nuciforo S, Heim MH. Organoids to model liver disease.
JHEP Rep. 2021;3:100198.
108. Driehuis E, Kretzschmar K, Clevers H. Establishment
of patient-derived cancer organoids for drug-screening doi: 10.1016/j.jhepr.2020.100198
applications. Nat Protoc. 2020;15:3380-3409. 120. Lewis-Israeli YR, Wasserman AH, Gabalski MA, et al.
Self-assembling human heart organoids for the modeling
doi: 10.1038/s41596-020-0379-4
of cardiac development and congenital heart disease. Nat
109. Yoshida GJ. Applications of patient-derived tumor xenograft Commun. 2021;12:5142.
models and tumor organoids. J Hematol Oncol. 2020;13:4.
doi: 10.1038/s41467-021-25329-5
doi: 10.1186/s13045-019-0829-z
121. Wang J, Chen X, Li R, et al. Standardization and consensus
110. Lee SH, Hu W, Matulay JT, et al. Tumor evolution and drug in the development and application of bone organoids.
response in patient-derived organoid models of bladder Theranostics. 2025;15:682.
cancer. Cell. 2018;173:515-528.e517.
doi: 10.7150/thno.105840
doi: 10.1016/j.cell.2018.03.017
122. Chen S, Chen X, Geng Z, Su J. The horizon of bone organoid:
111. Broutier L, Mastrogiovanni G, Verstegen MM, et al. Human A perspective on construction and application. Bioact Mater.
primary liver cancer-derived organoid cultures for disease 2022;18:15-25.
modeling and drug screening. Nat Med. 2017;23:1424-1435.
doi: 10.1016/j.bioactmat.2022.01.048
doi: 10.1038/nm.4438
123. Wang J, Wu Y, Li G, et al. Engineering large‐scale self‐
112. Park JC, Jang SY, Lee D, et al. A logical network-based drug- mineralizing bone organoids with bone matrix‐inspired
screening platform for Alzheimer’s disease representing hydroxyapatite hybrid bioinks. Adv Mater. 2024;36:e2309875.

Volume 1 Issue 1 (2025) 17 doi: 10.36922/OR025040007